Movement Disorders and Parkinson's Disease

Mayo Clinic is an internationally recognized leader in addressing the mechanisms of movement disorders associated with neurodegenerative disease and Parkinson's disease. Through focused collaborative efforts, we are integrating clinical discoveries with newly identified radiographic and biological biomarkers of disease and proceeding with an organizational efficiency that few institutions can match.

Our Movement Disorders Subspecialty Group is identifying early predictive clinical signs and new molecular biomarkers for Parkinson's disease. The research team is also investigating induced pluripotent cells, an emergent technology that may allow neuronal and cell repair from the development of stemlike cells taken from a skin biopsy. These investigations are focused on improving clinical outcomes.

The Department of Neurology at Mayo Clinic has a legacy of excellence in research and treatment of the full spectrum of movement disorders, including tremor, dystonia, myoclonus, chorea, ataxia and dyskinesias of both common and uncommon origin and presentation.

Collaborative research

Close collaboration amongst specialists provides patients with the highest standard of care. This standard is met not only by employing the latest technological advances but also in the depth of experience brought to bear on interpreting test results and clinical findings. Symptom management includes tests, therapies and neurosurgical techniques. Our innovative deep brain stimulation practice is one of the largest in the world.

Brain research in the Discovery and Translation Labs at Mayo Clinic's campus in Florida is focused on the molecular biology of Parkinson's disease and discovering the genetic causes, with the hope that better understanding will lead to new treatments.

Faculty members collaborating on basic and clinical research related to movement disorders and Parkinson's disease include: